Multicenter prospective phase II study of decitabine priming with low-dose idarubicin, cytarabine, and G-CSF in children with refractory or relapsed acute myeloid leukemia.
1/5 보강
No standard salvage regimen exists for relapsed/refractory (R/R) pediatric AML.
APA
Fan L, Gao L, et al. (2026). Multicenter prospective phase II study of decitabine priming with low-dose idarubicin, cytarabine, and G-CSF in children with refractory or relapsed acute myeloid leukemia.. Haematologica. https://doi.org/10.3324/haematol.2025.289170
MLA
Fan L, et al.. "Multicenter prospective phase II study of decitabine priming with low-dose idarubicin, cytarabine, and G-CSF in children with refractory or relapsed acute myeloid leukemia.." Haematologica, 2026.
PMID
41641646 ↗
Abstract 한글 요약
No standard salvage regimen exists for relapsed/refractory (R/R) pediatric AML. In this prospective, multicenter Phase II trial, 101 evaluable patients (.
같은 제1저자의 인용 많은 논문 (5)
- Exosomal IGFALS as a prognostic biomarker in hepatocellular Carcinoma: Associations with immune infiltration and clinical outcomes.
- Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrial.
- Global Burden and Future Trends of Gastrointestinal Cancers in Adolescents and Young Adults, 1990-2045: A Predictive Analysis.
- The efficacy of combination therapy versus monotherapy in patients with glioblastoma with abnormal epidermal growth factor receptor (EGFR) genes, a systematic review and network meta-analysis.
- A Child with Epileptic Seizure: A Case of Significantly Enhanced MVNT.